Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate to severe atopic dermatitis, meeting its primary and secondary ...

Publication: “High-Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma”, Lorenz Wirth, Whitney Weigel, Christopher T Stamper, Johan ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Its primary purpose is treatment, ensuring a robust evaluation of Dupilumab’s efficacy and safety. The study began on January 3, 2024, with primary completion expected in 2025.

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous pemphigoid, a rare blistering skin disease primarily affecting elderly patients.

Dupilumab treatment in patients with CRSwNP led to a healthier nasal microbiota by increasing beneficial bacteria like Lawsonella and Corynebacterium. The gut microbiota showed no effect, indicating ...

These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. U.S ...

Dupilumab, administered by subcutaneous injection, is the first targeted treatment to be approved in the United States for bullous pemphigoid, according to the company’s press release.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, ...

BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids ...

Abstract: Amicrobial pustulosis of the folds is a chronic relapsing neutrophilic dermatosis characterized by sterile pustules compromising skin folds, scalp, face and periorificial regions. It ...